The big successes of his recent career are not what motivate Cathal Friel. The executive chair and co-founder of Open Orphan and Poolbeg Pharma says his drive goes back to his teenage years in the early 1980s, when he had to drop out of school and take over the family’s retail and petrol business.
“Interest rates had gone through the roof that year, high double digits. My old boy had been dabbling with property in 1979, the economy was taking off, he borrowed quite a bit of money,” he says.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
